Inherited Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers [National Cancer Institute]“These findings raise the possibility that a high proportion of men with metastatic prostate cancer—1 in 8—may have germline mutations in DNA-repair genes,” said James Gulley, M.D., Ph.D., chief of the Genitourinary Malignancy Branch in NCI’s Center for Cancer Research, who was not involved in the research.
The study looked at immediate changes in smoking and alcohol consumption (in the last week) but longer-term follow-up would be needed to see if these decisions stuck or whether people reverted to their previous habits.
Dépistage, diagnostic et pronostic
Breast Cancer Screening (Mammography, MRI and Ultrasound) Market and Population Forecast to 2021 - Global Analysis Igate Research [ReportBuyer]In terms of breast cancer screening population, the countries such as United States, China, Japan, Germany and United Kingdom captures maximum share of the pie. In 2015, these five countries together accounted for over 60% share of the global breast cancer screening population. Brazil, Spain, Italy, France, South Korea and India are the other top contributors to the global breast cancer screening population.
ESMO Publishes Results of European Consortium Study on the Availability of Anti-neoplastic Medicines [ESMO]The study found that the differences in the formulary availability, out-of-pocket costs to patients and actual availability of many anti-cancer medicines are most profound in countries with lower levels of economic development, particularly in Eastern Europe, and are largely related to the cost of new agents developed and licensed in the past 10 years.
This research showed for the first time that an anti-malaria drug slows down the rate at which cancer cells use oxygen by targeting the mitochondria, the powerhouses of the cell that make energy, a process that uses oxygen.
Personalized Medicine Meets Thyroid Cancer: Drug Targeting BRAF Mutation Helps Patients [Penn Medicine]Vemurafenib Elicits a Response in a Third of Advanced Thyroid Cancer Patients with the BRAFV600E Mutation, Penn Study Finds.
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results [MIT News]In mice, device destroyed colorectal tumors and prevented remission after surgery.
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies [Kite Pharma]The artificial thymic organoid (ATO) system is an in vitro model that artificially mimics the thymic environment to recapitulate human T-cell development. The ATO system supports efficient differentiation and positive selection of normal T-cells using hematopoietic stem cells from various sources, as well as pluripotent stem cells, like embryonic stem cells and induced pluripotent stem cells.
FDA, EMA, ...
EMA will seek in particular to reduce the risks of studies that combine a number of different subtrials. Such studies are becoming more and more common, EMA writes.
Demonstrating significant benefit of orphan medicines: concepts, methodology and impact on access - workshop report [EMA]This was the first public workshop on this topic since the introduction of the orphan legislation in 2000.
As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent.
Revlimid sales are forecast to reach $6.7 billion this year, according to Celgene guidance. The company's 2020 financial guidance counts on expanded indications for Revlimid to deliver between $1 billion and $1.5 billion in new sales.
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen [AbbVie]Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC.
Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma [Janssen]Marks the second Breakthrough Therapy Designation for daratumumab.
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy [Shire]In a pivotal analysis, nal-IRI plus 5-FU/LV demonstrated a significant increase in median overall survival versus 5-FU and LV alone: 6.1 months vs 4.2 months.
Lutte contre les cancers
Venter, 69, has raised $300 million from investors that include GE Ventures, the biotech company Celgene, and Illumina, which supplies the sequencing machines.
To put it another way, we were, as GPs, being expected to refer 20 patients for every new diagnosis of cancer; now we should be referring 33. If our hit rate was as low as 5%, then we are now being asked to increase the number of referrals by around 65%.